Diabetes
PURLs
Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?
An RCT demonstrates that dapagliflozin produces better cardiovascular outcomes than placebo for heart failure patients with and without diabetes...
Applied Evidence
Transitioning patients with developmental disabilities to adult care
The pre-visit questionnaire, instructive videos, and Web resources detailed here can help you play a pivotal role in planning, commencing, and...
From the Journals
Cycling linked to longer life in people with type 2 diabetes
From the Journals
Statin safety, low muscle pain risk upheld in ‘reassuring’ study
The potential harms are small and the benefit-to-harm balance generally “favorable” for statin use in primary prevention of cardiovascular disease...
Conference Coverage
ADA/EASD draft guidance aims to bring adults with type 1 diabetes out of shadows
The new draft ADA/EASD consensus report offers an algorithm for diagnosing type 1 diabetes, a clear call for state-of-the-art technology, and an...
From the Journals
Metformin use may curb BCC risk
Population-based study shows a potential protective effect of metformin use for basal cell carcinoma, but no effect on risk of squamous cell...
Conference Coverage
New agents for youth-onset type 2 diabetes ‘finally in sight’
‘A number of clinical trials of antidiabetic pharmacologic agents in diabetic youth have been completed, demonstrating safety and efficacy, and a...
Commentary
Rising rates of T1D in children: Is COVID to blame?
With the pandemic came a noticeable rise in cases of new-onset type 1 diabetes in children. Dr. Jessica Sparks Lilley discusses possible...
Conference Coverage
Not so crazy: Pancreas transplants in type 2 diabetes rising
Simultaneous pancreas-kidney transplants are increasingly performed in patients with type 2 diabetes and chronic kidney disease.
From the Journals
South Asian ancestry associated with twice the risk of heart disease
Findings confirm previous reports identifying South Asian ancestry as a risk enhancer for atherosclerotic cardiovascular disease.
News
New drug, finerenone, approved for slowing kidney disease in diabetes
Finerenone (Kerendia) is the first agent approved from a novel class, the nonsteroidal mineralocorticoid receptor antagonists. But its role in...